Safe, Effective COVID-19 Vaccine with Peptide-Based Immunity
Highly Effective COVID-19 Vaccine Using Linked Immunodominant Linear Peptides from SARS-CoV2
Tags: The University of Hong Kong, Hong Kong, Healthcare & Lifesciences
Researchers have developed a highly effective COVID-19 vaccine using linked immunodominant linear peptides from SARS-CoV-2. This novel approach avoids the full cloning of the S protein, instead targeting specific immunodominant regions to generate robust neutralizing antibodies and cellular immune responses in animal models. The vaccine demonstrates improved safety and efficacy, particularly against variants of SARS-CoV-2, with strong disease mitigation in preclinical studies. Its non-viral formulation simplifies manufacturing, making it a scalable and safe option for next-generation COVID-19 vaccines. The innovation has been published in peer-reviewed research and is protected under a pending PCT patent.
IP Type or Form Factor: Patent Pending; Material; Process & Method
TRL: 4 - minimum viable product built in lab
Industry or Tech Area: Vaccines; Biotechnology
